[{"category":"Human","name_of_medicine":"Tranexamic acid","procedure_number":"PSUSA/00003006/202503","active_substances":"tranexamic acid","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"11/12/2025","first_published_date":"11/12/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/tranexamic-acid"},{"category":"Human","name_of_medicine":"Remsima","procedure_number":"X-149","active_substances":"infliximab","dhpc_type":"New contraindication","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AB02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"08/12/2025","first_published_date":"08/12/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/remsima"},{"category":"Human","name_of_medicine":"Libtayo","procedure_number":"","active_substances":"cemiplimab","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L01XC33","atcvet_code_veterinary":"","therapeutic_area_mesh":"Carcinoma, Squamous Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"10/11/2025","first_published_date":"10/11/2025","last_updated_date":"10/11/2025","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/libtayo"},{"category":"Human","name_of_medicine":"Lenalidomide Mylan","procedure_number":"","active_substances":"lenalidomide","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L04AX07","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Myeloma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"29/10/2025","first_published_date":"29/10/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/lenalidomide-mylan"},{"category":"Human","name_of_medicine":"Crysvita","procedure_number":"EMAVR0000261369","active_substances":"burosumab","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"M05BX05","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/10/2025","first_published_date":"20/10/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/crysvita"},{"category":"Human","name_of_medicine":"Leqembi","procedure_number":"EMA/VR/0000290573","active_substances":"Lecanemab","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"N06DX04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Cognitive Dysfunction;Alzheimer Disease","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"26/09/2025","first_published_date":"14/10/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/leqembi"},{"category":"Human","name_of_medicine":"Finasteride / dutasteride","procedure_number":"EMEA/H/A-31/1539","active_substances":"Finasteride;dutasteride","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"Finasteride- and dutasteride-containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/09/2025","first_published_date":"07/10/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/finasteride-dutasteride"},{"category":"Human","name_of_medicine":"Ixchiq","procedure_number":"EMEA/H/A-20/1540","active_substances":"Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated","dhpc_type":"Referral - Article 20 procedure","regulatory_outcome":"","referral_name":"Ixchiq","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Chikungunya virus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/09/2025","first_published_date":"23/09/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ixchiq-0"},{"category":"Human","name_of_medicine":"Rapamune","procedure_number":"","active_substances":"sirolimus","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Graft Rejection;Kidney Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/09/2025","first_published_date":"19/09/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/rapamune"},{"category":"Human","name_of_medicine":"Caspofungin","procedure_number":"","active_substances":"caspofungin","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/10/2025","first_published_date":"09/09/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/caspofungin"},{"category":"Human","name_of_medicine":"Clozapine","procedure_number":"","active_substances":"clozapine","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"08/09/2025","first_published_date":"09/09/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/clozapine"},{"category":"Human","name_of_medicine":"Evrysdi","procedure_number":"","active_substances":"risdiplam","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"M09AX10","atcvet_code_veterinary":"","therapeutic_area_mesh":"Muscular Atrophy, Spinal","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"21/08/2025","first_published_date":"21/08/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/evrysdi"},{"category":"Human","name_of_medicine":"Rybelsus","procedure_number":"","active_substances":"semaglutide","dhpc_type":"Medication error","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"A10BJ06","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"01/08/2025","first_published_date":"01/08/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/rybelsus"},{"category":"Human","name_of_medicine":"Ixchiq","procedure_number":"EMEA/H/A-20/1540","active_substances":"Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"Ixchiq","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Chikungunya virus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"22/05/2025","first_published_date":"28/05/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ixchiq"},{"category":"Human","name_of_medicine":"Opzelura","procedure_number":"","active_substances":"ruxolitinib phosphate","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"D11AH","atcvet_code_veterinary":"","therapeutic_area_mesh":"Vitiligo","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"24/04/2025","first_published_date":"24/04/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/opzelura"},{"category":"Human","name_of_medicine":"Emblaveo","procedure_number":"","active_substances":"avibactam;aztreonam","dhpc_type":"Quality defect","regulatory_outcome":"Suspension","referral_name":"","atc_code_human":"J01DF51","atcvet_code_veterinary":"","therapeutic_area_mesh":"Gram-Negative Bacterial Infections;Urinary Tract Infections;Healthcare-Associated Pneumonia;Soft Tissue Infections","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"14/03/2025","first_published_date":"20/03/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/emblaveo"},{"category":"Human","name_of_medicine":"Kisqali","procedure_number":"EMEA/H/C/004213/II/0045","active_substances":"ribociclib","dhpc_type":"Post-authorisation measure","regulatory_outcome":"","referral_name":"","atc_code_human":"L01EF02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Breast Neoplasms","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/02/2025","first_published_date":"24/02/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/kisqali"},{"category":"Human","name_of_medicine":"Veoza","procedure_number":"PSUSA/00000231/202405","active_substances":"fezolinetant","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"G02CX06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Menopause;Hot Flashes","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"13/01/2025","first_published_date":"23/01/2025","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/veoza"},{"category":"Human","name_of_medicine":"Alofisel","procedure_number":"","active_substances":"darvadstrocel","dhpc_type":"Lack of effect","regulatory_outcome":"Withdrawal","referral_name":"","atc_code_human":"L04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Rectal Fistula","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/12/2024","first_published_date":"19/12/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/alofisel"},{"category":"Human","name_of_medicine":"Keppra","procedure_number":"","active_substances":"levetiracetam","dhpc_type":"Medication error","regulatory_outcome":"","referral_name":"","atc_code_human":"N03AX14","atcvet_code_veterinary":"","therapeutic_area_mesh":"Epilepsy","species":"","other_related_medicines_nationally_authorised":"Levetiracetam UCB","dissemination_date":"16/12/2024","first_published_date":"18/12/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/keppra"},{"category":"Human","name_of_medicine":"Medroxyprogesterone acetate","procedure_number":"","active_substances":"medroxyprogesterone acetate","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"Medroxyprogesterone-containing medicines","dissemination_date":"03/10/2024","first_published_date":"16/12/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/medroxyprogesterone-acetate"},{"category":"Veterinary","name_of_medicine":"Kexxtone","procedure_number":"EMEA/V/C/002235","active_substances":"monensin (as monensin sodium)","dhpc_type":"Quality defect","regulatory_outcome":"Suspension","referral_name":"Kexxtone 32.4 g continuous-release intraruminal device for cattle","atc_code_human":"","atcvet_code_veterinary":"QA16QA06","therapeutic_area_mesh":"","species":"Cattle","other_related_medicines_nationally_authorised":"","dissemination_date":"05/06/2024","first_published_date":"05/06/2024","last_updated_date":"11/12/2024","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/kexxtone"},{"category":"Human","name_of_medicine":"Cyanokit","procedure_number":"","active_substances":"hydroxocobalamin","dhpc_type":"Medicine shortage;Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"V03AB33","atcvet_code_veterinary":"","therapeutic_area_mesh":"Poisoning","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/12/2024","first_published_date":"09/12/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/cyanokit"},{"category":"Human","name_of_medicine":"Ibandronic acid Accord","procedure_number":"","active_substances":"ibandronic acid","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"M05BA06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Wounds and Injuries;Breast Diseases;Neoplastic Processes;Calcium Metabolism Disorders;Water-Electrolyte Imbalance","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"05/12/2024","first_published_date":"05/12/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ibandronic-acid-accord"},{"category":"Human","name_of_medicine":"Metamizole","procedure_number":"EMEA/H/A-107i/1537","active_substances":"metamizole","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"Metamizole-containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"03/12/2024","first_published_date":"03/12/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/metamizole-0"},{"category":"Human","name_of_medicine":"Pegasys","procedure_number":"","active_substances":"peginterferon alfa-2a","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"L03AB11","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hepatitis C, Chronic;Hepatitis B, Chronic;Polycythemia Vera;Thrombocythemia, Essential","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"08/11/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/pegasys"},{"category":"Human","name_of_medicine":"5 fluorouracil","procedure_number":"PSUSA/00000007/202312","active_substances":"5 fluorouracil","dhpc_type":"Periodic safety update single assessment","regulatory_outcome":"","referral_name":"Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Neoplasms","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"24/10/2024","first_published_date":"24/10/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/5-fluorouracil"},{"category":"Human","name_of_medicine":"Vabysmo","procedure_number":"","active_substances":"Faricimab","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"S01L","atcvet_code_veterinary":"","therapeutic_area_mesh":"Wet Macular Degeneration;Macular Edema;Diabetes Complications","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/10/2024","first_published_date":"17/10/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vabysmo-0"},{"category":"Human","name_of_medicine":"Infanrix Hexa","procedure_number":"","active_substances":"Diphtheria toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide;tetanus toxoid","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"J07CA09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hepatitis B;Immunization;Meningitis;Haemophilus;Whooping Cough;Poliomyelitis;Diphtheria;Tetanus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"10/10/2024","first_published_date":"10/10/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/infanrix-hexa"},{"category":"Human","name_of_medicine":"Synflorix","procedure_number":"","active_substances":"Pneumococcal polysaccharide serotype 23F;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19F","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"J07AL52","atcvet_code_veterinary":"","therapeutic_area_mesh":"Pneumococcal Infections;Immunization","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"10/10/2024","first_published_date":"10/10/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/synflorix"},{"category":"Human","name_of_medicine":"Oxbryta","procedure_number":"EMEA/H/A-20/1538/C/004869/0014","active_substances":"voxelotor","dhpc_type":"Referral - Article 20 procedure","regulatory_outcome":"Suspension","referral_name":"Oxbryta","atc_code_human":"B06AX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Anemia;Anemia, Hemolytic;Anemia, Sickle Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"07/10/2024","first_published_date":"07/10/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/oxbryta"},{"category":"Human","name_of_medicine":"Ozempic / Victoza","procedure_number":"","active_substances":"semaglutide;liraglutide","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"A10BJ06;A10BJ02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus;Diabetes Mellitus, Type 2","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/08/2024","first_published_date":"02/09/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ozempic-victoza-0"},{"category":"Human","name_of_medicine":"Privigen","procedure_number":"","active_substances":"human normal immunoglobulin (IVIg)","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"J06BA02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Purpura;Bone Marrow Transplantation;Immunologic Deficiency Syndromes;Guillain-Barre Syndrome;Mucocutaneous Lymph Node Syndrome","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"22/08/2024","first_published_date":"22/08/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/privigen"},{"category":"Human","name_of_medicine":"NovoSeven","procedure_number":"EMEA/H/C/000074","active_substances":"eptacog alfa (activated)","dhpc_type":"Medicine shortage;Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"B02BD08","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hemophilia B;Thrombasthenia;Factor VII Deficiency;Hemophilia A","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/08/2024","first_published_date":"19/08/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/novoseven"},{"category":"Human","name_of_medicine":"Glatiramer acetate","procedure_number":"PSUSA/00001529/202311","active_substances":"Glatiramer acetate","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L03AX13","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Sclerosis","species":"","other_related_medicines_nationally_authorised":"Glatiramer acetate","dissemination_date":"14/08/2024","first_published_date":"14/08/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/glatiramer-acetate"},{"category":"Human","name_of_medicine":"Ocaliva","procedure_number":"","active_substances":"obeticholic acid","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Revocation","referral_name":"Ocaliva","atc_code_human":"A05AA04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Liver Cirrhosis, Biliary","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"31/07/2024","first_published_date":"31/07/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ocaliva-0"},{"category":"Human","name_of_medicine":"Vabysmo","procedure_number":"","active_substances":"Faricimab","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"S01L","atcvet_code_veterinary":"","therapeutic_area_mesh":"Wet Macular Degeneration;Macular Edema;Diabetes Complications","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"25/07/2024","first_published_date":"25/07/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vabysmo"},{"category":"Veterinary","name_of_medicine":"Senvelgo","procedure_number":"EMEA/V/C/005972","active_substances":"velagliflozin L-proline monohydrate","dhpc_type":"Adverse event","regulatory_outcome":"","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"QA10BK90","therapeutic_area_mesh":"","species":"Cats","other_related_medicines_nationally_authorised":"","dissemination_date":"19/07/2024","first_published_date":"19/07/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/senvelgo"},{"category":"Human","name_of_medicine":"Abecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta","procedure_number":"","active_substances":"idecabtagene vicleucel;lisocabtagene maraleucel;tisagenlecleucel;brexucabtagene autoleucel;axicabtagene ciloleucel;ciltacabtagene autoleucel","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01;L01XL05;L01XL04;L01X;L01XX70","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Myeloma;Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Lymphoma, Mantle-Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"18/07/2024","first_published_date":"18/07/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/abecma-breyanzi-carvykti-kymriah-tecartus-yescarta"},{"category":"Human","name_of_medicine":"Hydroxyprogesterone caproate","procedure_number":"EMEA-H-A-31-1528","active_substances":"hydroxyprogesterone caproate","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Suspension","referral_name":"Hydroxyprogesterone caproate-containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"Lentogest; Progesterone Retard Pharlon; Proluton Depot","dissemination_date":"17/07/2024","first_published_date":"17/07/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/hydroxyprogesterone-caproate"},{"category":"Human","name_of_medicine":"Zypadhera","procedure_number":"","active_substances":"olanzapine pamoate monohydrate","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"N05AH03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Schizophrenia","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/06/2024","first_published_date":"19/06/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/zypadhera"},{"category":"Human","name_of_medicine":"Giapreza","procedure_number":"","active_substances":"angiotensin II acetate","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"C09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypotension;Shock","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/05/2024","first_published_date":"23/05/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/giapreza"},{"category":"Human","name_of_medicine":"Paxlovid","procedure_number":"","active_substances":"nirmatrelvir;ritonavir","dhpc_type":"Adverse event","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"J05AE30","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"21/03/2024","first_published_date":"21/03/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/paxlovid"},{"category":"Human","name_of_medicine":"Valproate","procedure_number":"EMEA/H/N/PSR/J/0043","active_substances":"valproate","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"N03AG01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Epilepsy;Bipolar Disorder;Migraine Disorders","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/02/2024","first_published_date":"19/02/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/valproate"},{"category":"Human","name_of_medicine":"Pseudoephedrine","procedure_number":"EMEA/H/A-31/1526","active_substances":"pseudoephedrine","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Pseudoephedrine-containing medicinal products","atc_code_human":"R01BA02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Nasal Decongestants","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/02/2024","first_published_date":"08/02/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/pseudoephedrine"},{"category":"Human","name_of_medicine":"Voxzogo","procedure_number":"EMEA/H/C/005475/II/0007","active_substances":"vosoritide","dhpc_type":"Change in dosing recommendation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"M05BX","atcvet_code_veterinary":"","therapeutic_area_mesh":"Achondroplasia","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"23/01/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/voxzogo"},{"category":"Human","name_of_medicine":"Leqvio","procedure_number":"","active_substances":"inclisiran","dhpc_type":"Quality defect","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"C10AX","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypercholesterolemia;Dyslipidemias","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"21/12/2023","first_published_date":"23/01/2024","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/leqvio"},{"category":"Human","name_of_medicine":"Integrilin","procedure_number":"","active_substances":"eptifibatide","dhpc_type":"Medicine shortage","regulatory_outcome":"Withdrawal","referral_name":"","atc_code_human":"B01AC16","atcvet_code_veterinary":"","therapeutic_area_mesh":"Angina, Unstable;Myocardial Infarction","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"02/11/2023","first_published_date":"04/12/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/integrilin"},{"category":"Human","name_of_medicine":"Ozempic / Victoza","procedure_number":"","active_substances":"semaglutide;liraglutide","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"A10BJ06;A10BJ02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus, Type 2","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"21/11/2023","last_updated_date":"01/12/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ozempic-victoza"},{"category":"Human","name_of_medicine":"Omega-3 fatty acid ethyl esters","procedure_number":"","active_substances":"omega-3 fatty acid ethyl esters","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Cardiovascular Diseases","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"08/11/2023","first_published_date":"01/12/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/omega-3-fatty-acid-ethyl-esters"},{"category":"Human","name_of_medicine":"Topiramate / phentermine","procedure_number":"EMEA/H/A-31/1520","active_substances":"topiramate;phentermine","dhpc_type":"Restriction of indication","regulatory_outcome":"Variation","referral_name":"Topiramate","atc_code_human":"N03AX11","atcvet_code_veterinary":"","therapeutic_area_mesh":"Epilepsy;Migraine Disorders","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"01/11/2023","first_published_date":"21/11/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/topiramate-phentermine"},{"category":"Human","name_of_medicine":"Vaxneuvance","procedure_number":"","active_substances":"Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)","dhpc_type":"Quality defect","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"J07AL02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Pneumococcal Infections","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"20/09/2023","first_published_date":"20/09/2023","last_updated_date":"20/09/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vaxneuvance"},{"category":"Human","name_of_medicine":"RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq","procedure_number":"","active_substances":"tocilizumab;emicizumab;trastuzumab;trastuzumab emtansine;rituximab;pertuzumab;trastuzumab;atezolizumab","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L04AC07;B02BX06;L01XC03;L01XC14;L01XC02;L01XY","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection;Hemophilia A;Stomach Neoplasms;Breast Neoplasms;Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell;Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Small Cell Lung Carcinoma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/08/2023","first_published_date":"17/08/2023","last_updated_date":"17/08/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/roactemra-hemlibra-herceptin-kadcyla-mabthera-phesgo-tecentriq"},{"category":"Human","name_of_medicine":"Advate / Rixubis","procedure_number":"","active_substances":"octocog alfa;Factor VIII Inhibitor Bypassing Activity;nonacog gamma","dhpc_type":"Quality defect","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"14/08/2023","first_published_date":"14/08/2023","last_updated_date":"14/08/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/advate-rixubis"},{"category":"Human","name_of_medicine":"Simponi","procedure_number":"","active_substances":"golimumab","dhpc_type":"Quality defect","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AB06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Arthritis, Rheumatoid","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/08/2023","first_published_date":"10/08/2023","last_updated_date":"10/08/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/simponi"},{"category":"Human","name_of_medicine":"Gavreto","procedure_number":"EMEA/H/C/005413","active_substances":"pralsetinib","dhpc_type":"Adverse event;Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01XE","atcvet_code_veterinary":"","therapeutic_area_mesh":"Carcinoma, Non-Small-Cell Lung","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"16/06/2023","first_published_date":"16/06/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/gavreto"},{"category":"Human","name_of_medicine":"Adakveo","procedure_number":"EMEA/H/A-20/1525/C/4874/0013","active_substances":"Crizanlizumab","dhpc_type":"Lack of effect;Referral - Article 20 procedure","regulatory_outcome":"Revocation","referral_name":"","atc_code_human":"B06AX01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Anemia, Sickle Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"15/06/2023","first_published_date":"15/06/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/adakveo-0"},{"category":"Human","name_of_medicine":"Fluoroquinolones","procedure_number":"SC01/EMA/2018/29/PE","active_substances":"Fluoroquinolones","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"Quinolone- and fluoroquinolone-containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Anti-Bacterial Agents","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"08/06/2023","first_published_date":"08/06/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/fluoroquinolones"},{"category":"Veterinary","name_of_medicine":"Arti-Cell Forte / RenuTend","procedure_number":"","active_substances":"Equine allogeneic mesenchymal stem cells","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"QM09AX90","therapeutic_area_mesh":"","species":"Horses","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"04/05/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/arti-cell-forte-renutend"},{"category":"Human","name_of_medicine":"Simulect","procedure_number":"EMEA/H/C/000207","active_substances":"basiliximab","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L04AC02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Graft Rejection;Kidney Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"21/04/2023","first_published_date":"20/04/2023","last_updated_date":"21/04/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/simulect"},{"category":"Human","name_of_medicine":"Menotropin","procedure_number":"DK/H/0606/01-06/DC","active_substances":"Menotropin","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"G03GA02","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"Menopur","dissemination_date":"12/04/2023","first_published_date":"17/04/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/menotropin"},{"category":"Human","name_of_medicine":"Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz","procedure_number":"EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014","active_substances":"abrocitinib;filgotinib;Baricitinib;upadacitinib;tofacitinib","dhpc_type":"Referral - Article 20 procedure","regulatory_outcome":"Variation","referral_name":"Janus kinase inhibitors (JAKi)","atc_code_human":"D11AH08;L04AA45;L04AA37;L04AA44;L04AA29","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Rheumatoid;Dermatitis, Atopic","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"21/02/2023","first_published_date":"30/03/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/cibinqo-jyseleca-olumiant-rinvoq-xeljanz"},{"category":"Human","name_of_medicine":"Pholcodine","procedure_number":"EMEA/H/A-107i/1521","active_substances":"Pholcodine","dhpc_type":"Referral - Article 107i procedure","regulatory_outcome":"Revocation","referral_name":"Pholcodine-containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Cough","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"27/03/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/pholcodine"},{"category":"Human","name_of_medicine":"Myalepta","procedure_number":"EMEA/H/C/004218","active_substances":"Metreleptin","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"A16AA","atcvet_code_veterinary":"","therapeutic_area_mesh":"Lipodystrophy, Familial Partial","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"03/03/2023","first_published_date":"14/03/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/myalepta-0"},{"category":"Human","name_of_medicine":"Ozempic","procedure_number":"EMEA/H/C/004174","active_substances":"semaglutide","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"A10BJ06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"13/03/2023","first_published_date":"13/03/2023","last_updated_date":"13/03/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ozempic-0"},{"category":"Human","name_of_medicine":"Caprelsa","procedure_number":"EMEA/H/C/002315/II/0043","active_substances":"vandetanib","dhpc_type":"Restriction of indication","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01XE","atcvet_code_veterinary":"","therapeutic_area_mesh":"Thyroid Neoplasms","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"28/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/caprelsa"},{"category":"Human","name_of_medicine":"Xalkori","procedure_number":"EMEA/H/C/002489/II/0072","active_substances":"crizotinib","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01ED01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Carcinoma, Non-Small-Cell Lung","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"21/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/xalkori"},{"category":"Human","name_of_medicine":"Spikevax (previously COVID-19 Vaccine Moderna)","procedure_number":"","active_substances":"CX-024414 (single-stranded, 5â€™-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"21/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/spikevax-previously-covid-19-vaccine-moderna"},{"category":"Human","name_of_medicine":"Terlipressin","procedure_number":"EMEA/H/A-31/1514","active_substances":"terlipressin","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Terlipressin-containing medicinal products indicated in the treatment of hepatorenal syndrome","atc_code_human":"H01BA04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Vasopressins","species":"","other_related_medicines_nationally_authorised":"Glypressin, Terlipressin Acetate and Variquel","dissemination_date":"01/12/2022","first_published_date":"17/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/terlipressin"},{"category":"Human","name_of_medicine":"Zolgensma","procedure_number":"EMEA/H/C/004750/II/0033/G","active_substances":"onasemnogene abeparvovec","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"M09AX09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Muscular Atrophy, Spinal","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"16/02/2023","first_published_date":"17/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/zolgensma-0"},{"category":"Human","name_of_medicine":"Neofordex","procedure_number":"EMEA/H/C/004071/II/0017-G","active_substances":"dexamethasone","dhpc_type":"Change in dosing recommendation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"H02AB02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Myeloma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/02/2023","first_published_date":"17/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/neofordex"},{"category":"Human","name_of_medicine":"Fasturtec","procedure_number":"EMEA/H/C/000331","active_substances":"rasburicase","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"V03AF07","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hyperuricemia","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/02/2023","first_published_date":"17/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/fasturtec"},{"category":"Human","name_of_medicine":"Cystagon","procedure_number":"EMEA/H/C/000125","active_substances":"mercaptamine bitartrate","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"A16AA04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Cystinosis","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"15/02/2023","first_published_date":"15/02/2023","last_updated_date":"15/02/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/cystagon"},{"category":"Human","name_of_medicine":"Adakveo","procedure_number":"EMEA/H/C/004874","active_substances":"Crizanlizumab","dhpc_type":"Referral - Article 20 procedure","regulatory_outcome":"","referral_name":"Adakveo","atc_code_human":"B06AX01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Anemia, Sickle Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"14/02/2023","first_published_date":"14/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/adakveo"},{"category":"Human","name_of_medicine":"Amfepramone","procedure_number":"EMEA/H/A-31/1501","active_substances":"amfepramone","dhpc_type":"Referral - Article 31","regulatory_outcome":"Revocation","referral_name":"Amfepramone-containing medicinal products","atc_code_human":"A08AA03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Obesity","species":"","other_related_medicines_nationally_authorised":"Regenon; Tenuate Retard; Amfepramon-Hormosan; Regenon Retard","dissemination_date":"08/02/2023","first_published_date":"08/02/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/amfepramone"},{"category":"Human","name_of_medicine":"Lymphoseek","procedure_number":"EMEA/H/C/002085","active_substances":"tilmanocept","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"V09IA09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Radionuclide Imaging","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"31/01/2023","first_published_date":"31/01/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/lymphoseek-1"},{"category":"Human","name_of_medicine":"Pazenir","procedure_number":"EMEA/H/C/004441","active_substances":"paclitaxel","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"L01CD01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Breast Neoplasms","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"24/01/2023","first_published_date":"25/01/2023","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/pazenir"},{"category":"Human","name_of_medicine":"Insuman","procedure_number":"EMEA/H/C/000201","active_substances":"Insulin human","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"A10AB01;A10AC01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"14/01/2023","first_published_date":"16/01/2023","last_updated_date":"16/01/2023","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/insuman-0"},{"category":"Human","name_of_medicine":"Zoely","procedure_number":"EMEA/H/A-31/1510","active_substances":"nomegestrol;chlormadinone","dhpc_type":"Adverse event;Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Nomegestrol and chlormadinone","atc_code_human":"G03","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"08/11/2022","first_published_date":"08/11/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/zoely"},{"category":"Human","name_of_medicine":"Imbruvica","procedure_number":"EMEA/H/C/003791/II/0075","active_substances":"Ibrutinib","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01EL01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Lymphoma, Mantle-Cell;Leukemia, Lymphocytic, Chronic, B-Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"03/11/2022","first_published_date":"03/11/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/imbruvica"},{"category":"Human","name_of_medicine":"Ozempic","procedure_number":"","active_substances":"semaglutide","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"A10BJ06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/10/2022","first_published_date":"19/10/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ozempic"},{"category":"Human","name_of_medicine":"Natpar","procedure_number":"EMEA/H/C/003861","active_substances":"parathyroid hormone","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"H05AA03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypoparathyroidism","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"04/10/2022","first_published_date":"04/10/2022","last_updated_date":"04/10/2022","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/natpar-0"},{"category":"Human","name_of_medicine":"Nulojix","procedure_number":"EMEA/H/C/002098","active_substances":"belatacept","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"L04AA28","atcvet_code_veterinary":"","therapeutic_area_mesh":"Graft Rejection;Kidney Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"28/09/2022","first_published_date":"27/09/2022","last_updated_date":"28/09/2022","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/nulojix-2"},{"category":"Human","name_of_medicine":"Metalyse","procedure_number":"EMEA/H/C/000306","active_substances":"tenecteplase","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"B01AD11","atcvet_code_veterinary":"","therapeutic_area_mesh":"Myocardial Infarction","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/09/2022","first_published_date":"23/09/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/metalyse"},{"category":"Human","name_of_medicine":"Nulojix","procedure_number":"EMEA/H/C/002098/II/0079/G","active_substances":"belatacept","dhpc_type":"Medication error","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"L04AA28","atcvet_code_veterinary":"","therapeutic_area_mesh":"Graft Rejection;Kidney Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/09/2022","first_published_date":"12/09/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/nulojix-1"},{"category":"Human","name_of_medicine":"Visudyne","procedure_number":"EMEA/H/C/000305","active_substances":"verteporfin","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"S01LA01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Myopia, Degenerative;Macular Degeneration","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/08/2022","first_published_date":"12/08/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/visudyne-0"},{"category":"Veterinary","name_of_medicine":"Hiprabovis IBR Marker Live","procedure_number":"EMEA/V/C/000158","active_substances":"live gE- tk- double-gene-deleted bovine herpes virus type 1, strain CEDDEL: 106.3â€“107.3 CCID50","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"QI02AD01","therapeutic_area_mesh":"","species":"Cattle","other_related_medicines_nationally_authorised":"","dissemination_date":"11/08/2022","first_published_date":"11/08/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/hiprabovis-ibr-marker-live"},{"category":"Human","name_of_medicine":"Cetrotide","procedure_number":"EMEA/H/C/000233","active_substances":"cetrorelix (as acetate)","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"H01CC02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Ovulation;Ovulation Induction","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/08/2022","first_published_date":"09/08/2022","last_updated_date":"09/08/2022","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/cetrotide"},{"category":"Human","name_of_medicine":"Rubraca","procedure_number":"EMEA/H/A-20/1518/C/4272/0033","active_substances":"Rucaparib camsylate","dhpc_type":"Referral - Article 20 procedure;Restriction of indication","regulatory_outcome":"Variation","referral_name":"Rubraca","atc_code_human":"L01XX","atcvet_code_veterinary":"","therapeutic_area_mesh":"Ovarian Neoplasms","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/08/2022","first_published_date":"08/08/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/rubraca"},{"category":"Human","name_of_medicine":"Hydroxyethyl starch","procedure_number":"","active_substances":"hydroxyethyl starch","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Suspension","referral_name":"Hydroxyethyl starch (HES) containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"30/06/2022","first_published_date":"30/06/2022","last_updated_date":"26/07/2022","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/hydroxyethyl-starch"},{"category":"Human","name_of_medicine":"Imlygic","procedure_number":"EMEA/H/C/002771","active_substances":"talimogene laherparepvec","dhpc_type":"Adverse event;Quality defect","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01XX51","atcvet_code_veterinary":"","therapeutic_area_mesh":"Melanoma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"16/06/2022","first_published_date":"16/06/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/imlygic"},{"category":"Human","name_of_medicine":"Dexdor","procedure_number":"EMEA/H/C/002268/II/0035","active_substances":"Dexmedetomidine hydrochloride","dhpc_type":"Safety signal","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"N05CM18","atcvet_code_veterinary":"","therapeutic_area_mesh":"Conscious Sedation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"16/06/2022","first_published_date":"16/06/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/dexdor"},{"category":"Human","name_of_medicine":"Defitelio","procedure_number":"EMEA/H/C/004093/II/0030","active_substances":"defibrotide","dhpc_type":"Lack of effect;Safety signal","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"B01AX01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hepatic Veno-Occlusive Disease","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"13/06/2022","first_published_date":"13/06/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/defitelio"},{"category":"Human","name_of_medicine":"Ocaliva","procedure_number":"EMEA/H/C/004093/II/0030","active_substances":"obeticholic acid","dhpc_type":"New contraindication","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"A05AA04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Liver Cirrhosis, Biliary","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/06/2022","first_published_date":"09/06/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ocaliva"},{"category":"Human","name_of_medicine":"Lymphoseek","procedure_number":"EMEA/H/C/002085","active_substances":"tilmanocept","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"V09IA09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Radionuclide Imaging","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"30/05/2022","first_published_date":"30/05/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/lymphoseek-0"},{"category":"Human","name_of_medicine":"Rubraca","procedure_number":"EMEA/H/A-20/1518/C/4272/0033","active_substances":"Rucaparib camsylate","dhpc_type":"Referral - Article 20 procedure","regulatory_outcome":"Variation","referral_name":"Rubraca","atc_code_human":"L01XX","atcvet_code_veterinary":"","therapeutic_area_mesh":"Ovarian Neoplasms","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"05/05/2022","first_published_date":"06/05/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/rubraca-0"},{"category":"Human","name_of_medicine":"Natpar","procedure_number":"EMEA/H/C/003861","active_substances":"parathyroid hormone","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"H05AA03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypoparathyroidism","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"29/04/2022","first_published_date":"29/04/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/natpar"},{"category":"Human","name_of_medicine":"Remicade / Flixabi / Inflectra / Remsima / Zessly","procedure_number":"EMEA/H/C/000240/IB/233","active_substances":"infliximab","dhpc_type":"New contraindication","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AB02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Spondylitis, Ankylosing;Arthritis, Rheumatoid;Psoriasis;Crohn Disease;Arthritis, Psoriatic;Colitis, Ulcerative","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"07/03/2022","first_published_date":"07/03/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/remicade-flixabi-inflectra-remsima-zessly"},{"category":"Human","name_of_medicine":"Xagrid","procedure_number":"EMEA/H/C/000480/II/091","active_substances":"anagrelide","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01XX35","atcvet_code_veterinary":"","therapeutic_area_mesh":"Thrombocythemia, Essential","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"22/02/2022","first_published_date":"22/02/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/xagrid"},{"category":"Human","name_of_medicine":"Mavenclad","procedure_number":"","active_substances":"Cladribine","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AA40","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Sclerosis","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"14/02/2022","first_published_date":"14/02/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/mavenclad"},{"category":"Human","name_of_medicine":"Nulojix","procedure_number":"","active_substances":"belatacept","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"L04AA28","atcvet_code_veterinary":"","therapeutic_area_mesh":"Graft Rejection;Kidney Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/01/2022","first_published_date":"17/01/2022","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/nulojix-0"},{"category":"Human","name_of_medicine":"Briviact (in Italy: Nubriveo)","procedure_number":"","active_substances":"Brivaracetam","dhpc_type":"Quality defect","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"N03AX23","atcvet_code_veterinary":"","therapeutic_area_mesh":"Epilepsy","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"18/12/2021","first_published_date":"20/12/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/briviact-italy-nubriveo"},{"category":"Human","name_of_medicine":"Lymphoseek","procedure_number":"","active_substances":"tilmanocept","dhpc_type":"Medicine shortage","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"V09IA09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Radionuclide Imaging","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"07/12/2021","first_published_date":"07/12/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/lymphoseek"},{"category":"Human","name_of_medicine":"Forxiga","procedure_number":"EMEA/H/C/002322/II/0071","active_substances":"dapagliflozin propanediol monohydrate","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"A10BK01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus, Type 2","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"11/11/2021","first_published_date":"11/11/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/forxiga"},{"category":"Human","name_of_medicine":"Kevzara","procedure_number":"","active_substances":"sarilumab","dhpc_type":"Medicine shortage","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AC14","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Rheumatoid","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"09/11/2021","first_published_date":"09/11/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/kevzara"},{"category":"Human","name_of_medicine":"Beovu","procedure_number":"EMEA/H/C/004913","active_substances":"Brolucizumab","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"S01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Wet Macular Degeneration","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"05/11/2021","first_published_date":"05/11/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/beovu"},{"category":"Human","name_of_medicine":"Visudyne","procedure_number":"","active_substances":"verteporfin","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"S01LA01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Myopia, Degenerative;Macular Degeneration","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"05/11/2021","first_published_date":"05/11/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/visudyne"},{"category":"Human","name_of_medicine":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","procedure_number":"","active_substances":"ChAdOx1-SARS-COV-2","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"13/10/2021","first_published_date":"13/10/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-3"},{"category":"Human","name_of_medicine":"Jcovden (previously COVID-19 Vaccine Janssen)","procedure_number":"EMEA/H/C/005737","active_substances":"adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"13/10/2021","first_published_date":"13/10/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen-1"},{"category":"Human","name_of_medicine":"Champix","procedure_number":"","active_substances":"varenicline","dhpc_type":"Medicine shortage","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"N07BA03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Tobacco Use Cessation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"30/09/2021","first_published_date":"30/09/2021","last_updated_date":"30/09/2021","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/champix-0"},{"category":"Human","name_of_medicine":"RoActemra","procedure_number":"","active_substances":"tocilizumab","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"L04AC07","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"03/09/2020","first_published_date":"02/09/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/roactemra"},{"category":"Human","name_of_medicine":"Jcovden (previously COVID-19 Vaccine Janssen)","procedure_number":"EMEA/H/C/005737","active_substances":"adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/07/2021","first_published_date":"19/07/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen-0"},{"category":"Human","name_of_medicine":"Comirnaty / Spikevax (previously COVID-19 Vaccine Moderna)","procedure_number":"EMEA/H/C/005735; EMEA/H/C/005791","active_substances":"single-stranded, 5â€™-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2;CX-024414 (single-stranded, 5â€™-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX;J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"19/07/2021","first_published_date":"19/07/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/comirnaty-spikevax-previously-covid-19-vaccine-moderna"},{"category":"Human","name_of_medicine":"Champix","procedure_number":"EMEA/H/C/000699","active_substances":"varenicline","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"N07BA03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Tobacco Use Cessation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"15/07/2021","first_published_date":"15/07/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/champix"},{"category":"Human","name_of_medicine":"Xeljanz","procedure_number":"EMEA/H/C/004214","active_substances":"tofacitinib citrate","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AA29","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Rheumatoid","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"06/07/2021","first_published_date":"06/07/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/xeljanz-0"},{"category":"Human","name_of_medicine":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","procedure_number":"","active_substances":"ChAdOx1-SARS-COV-2","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/06/2021","first_published_date":"23/06/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-2"},{"category":"Human","name_of_medicine":"Venclyxto","procedure_number":"EMEA/H/C/004106/II/0031","active_substances":"venetoclax","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01XX52","atcvet_code_veterinary":"","therapeutic_area_mesh":"Leukemia, Lymphocytic, Chronic, B-Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"10/06/2021","first_published_date":"10/06/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/venclyxto"},{"category":"Human","name_of_medicine":"INOmax","procedure_number":"EMEA/H/C/000337","active_substances":"nitric oxide","dhpc_type":"Quality defect","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"R07AX","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypertension, Pulmonary;Respiratory Insufficiency","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"03/06/2021","first_published_date":"03/06/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/inomax"},{"category":"Human","name_of_medicine":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","procedure_number":"EMEA/H/C/005675/II/0014","active_substances":"ChAdOx1-SARS-COV-2","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"02/06/2021","first_published_date":"02/06/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-1"},{"category":"Human","name_of_medicine":"Jcovden (previously COVID-19 Vaccine Janssen)","procedure_number":"","active_substances":"adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"26/04/2021","first_published_date":"26/04/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen"},{"category":"Human","name_of_medicine":"Eylea","procedure_number":"EMEA/H/C/002392/II/0068","active_substances":"aflibercept","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"S01LA05","atcvet_code_veterinary":"","therapeutic_area_mesh":"Wet Macular Degeneration;Macular Edema;Diabetes Complications","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"15/04/2021","first_published_date":"15/04/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/eylea"},{"category":"Human","name_of_medicine":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","procedure_number":"","active_substances":"ChAdOx1-SARS-COV-2","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"13/04/2021","first_published_date":"13/04/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-0"},{"category":"Human","name_of_medicine":"Respreeza","procedure_number":"EMEA/H/C/002739","active_substances":"human alpha1-proteinase inhibitor","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"B02AB02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Genetic Diseases, Inborn;Lung Diseases","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"26/03/2021","first_published_date":"26/03/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/respreeza-0"},{"category":"Human","name_of_medicine":"Tecentriq","procedure_number":"EMEA/H/C/00414/II/0054","active_substances":"atezolizumab","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L01FX06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"25/03/2021","first_published_date":"18/03/2021","last_updated_date":"25/03/2021","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/tecentriq"},{"category":"Human","name_of_medicine":"Xeljanz","procedure_number":"","active_substances":"tofacitinib citrate","dhpc_type":"Safety signal","regulatory_outcome":"","referral_name":"","atc_code_human":"L04AA29","atcvet_code_veterinary":"","therapeutic_area_mesh":"Arthritis, Rheumatoid","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"24/03/2021","first_published_date":"24/03/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/xeljanz"},{"category":"Human","name_of_medicine":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","procedure_number":"","active_substances":"Chimpanzee Adenovirus encoding the SARS CoV 2 Spike glycoprotein (ChAdOx1-S)","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J07BX03","atcvet_code_veterinary":"","therapeutic_area_mesh":"COVID-19 virus infection","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"24/03/2021","first_published_date":"24/03/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca"},{"category":"Human","name_of_medicine":"Strimvelis","procedure_number":"EMEA/H/C/003854/R/0029","active_substances":"autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells","dhpc_type":"Adverse event","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"L03","atcvet_code_veterinary":"","therapeutic_area_mesh":"Severe Combined Immunodeficiency","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"22/03/2021","first_published_date":"22/03/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/strimvelis"},{"category":"Human","name_of_medicine":"Zolgensma","procedure_number":"EMEA/H/C/004750/II/0008","active_substances":"onasemnogene abeparvovec","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"M09AX09","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"18/03/2021","first_published_date":"18/03/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/zolgensma"},{"category":"Human","name_of_medicine":"Lojuxta","procedure_number":"EMEA/H/C/002578/S/0043","active_substances":"Lomitapide","dhpc_type":"Post-authorisation measure","regulatory_outcome":"Maintenance","referral_name":"","atc_code_human":"C10AX12","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hypercholesterolemia","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/02/2021","first_published_date":"17/02/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/lojuxta"},{"category":"Human","name_of_medicine":"Respreeza","procedure_number":"","active_substances":"alpha1-proteinase inhibitor (human)","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"B02AB02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Lung Diseases","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/02/2021","first_published_date":"12/02/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/respreeza"},{"category":"Human","name_of_medicine":"Alkindi","procedure_number":"","active_substances":"hydrocortisone","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"H02AB09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Adrenal Insufficiency","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"04/02/2021","first_published_date":"04/02/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/alkindi"},{"category":"Human","name_of_medicine":"Nucala","procedure_number":"","active_substances":"Mepolizumab","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"R03DX09","atcvet_code_veterinary":"","therapeutic_area_mesh":"Asthma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/01/2021","first_published_date":"27/01/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/nucala"},{"category":"Human","name_of_medicine":"Kaletra","procedure_number":"EMEA/H/C/000368","active_substances":"lopinavir;ritonavir","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"HIV Infections","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/12/2020","first_published_date":"04/01/2021","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/kaletra"},{"category":"Human","name_of_medicine":"Zerbaxa","procedure_number":"EMEA/H/C/003772","active_substances":"ceftolozane;tazobactam","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"J01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Bacterial Infections","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/12/2020","first_published_date":"22/12/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/zerbaxa"},{"category":"Human","name_of_medicine":"Metamizole","procedure_number":"PSUSA-00001997-202003","active_substances":"metamizole","dhpc_type":"Periodic safety update report","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"N02BB02","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"15/12/2020","first_published_date":"15/12/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/metamizole"},{"category":"Human","name_of_medicine":"Gliolan","procedure_number":"EMEA/H/C/000744/II/0018/G","active_substances":"5-aminolevulinic acid hydrochloride","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"Cyproterone-containing medicinal products","atc_code_human":"L01XD04","atcvet_code_veterinary":"","therapeutic_area_mesh":"Glioma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"01/12/2020","first_published_date":"01/12/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/gliolan"},{"category":"Human","name_of_medicine":"Tecfidera","procedure_number":"EMEA/H/C/002601/II/0063","active_substances":"dimethyl fumarate","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AX07","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Sclerosis","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/11/2020","first_published_date":"12/11/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/tecfidera"},{"category":"Human","name_of_medicine":"Gilenya","procedure_number":"EMEA/H/C/PSUSA/00001393/202002","active_substances":"Fingolimod","dhpc_type":"Periodic safety update report","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AA27","atcvet_code_veterinary":"","therapeutic_area_mesh":"Multiple Sclerosis","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"10/11/2020","first_published_date":"10/11/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/gilenya"},{"category":"Human","name_of_medicine":"Ondexxya","procedure_number":"EMEA/H/C/004108/II/0011","active_substances":"andexanet alfa","dhpc_type":"Adverse event","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"V03AB","atcvet_code_veterinary":"","therapeutic_area_mesh":"Drug-Related Side Effects and Adverse Reactions","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"04/11/2020","first_published_date":"04/11/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ondexxya-0"},{"category":"Human","name_of_medicine":"Esbriet","procedure_number":"EMEA/H/C/002154/II/0066/G","active_substances":"Pirfenidone","dhpc_type":"Type II variation","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"L04AX05","atcvet_code_veterinary":"","therapeutic_area_mesh":"Idiopathic Pulmonary Fibrosis","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"29/10/2020","first_published_date":"29/10/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/esbriet"},{"category":"Human","name_of_medicine":"Quofenix / Quinsair","procedure_number":"","active_substances":"Delafloxacin;levofloxacin","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J01MA23;J01MA12","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"Ciprofloxacin; Levofloxacin; Lomefloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Pefloxacin; Prulifloxacin; Rufloxacin","dissemination_date":"29/10/2020","first_published_date":"29/10/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/quofenix-quinsair"},{"category":"Human","name_of_medicine":"Cabazitaxel Accord","procedure_number":"EMEA/H/C/005178","active_substances":"cabazitaxel","dhpc_type":"Medication error","regulatory_outcome":"","referral_name":"","atc_code_human":"L01CD","atcvet_code_veterinary":"","therapeutic_area_mesh":"Prostatic Neoplasms, Castration-Resistant","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"28/10/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/cabazitaxel-accord"},{"category":"Human","name_of_medicine":"Leuprorelin","procedure_number":"EMEA/H/A-31/1486","active_substances":"leuprorelin","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Leuprorelin-containing depot medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"02/10/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/leuprorelin"},{"category":"Human","name_of_medicine":"Nulojix","procedure_number":"","active_substances":"belatacept","dhpc_type":"Medicine shortage","regulatory_outcome":"","referral_name":"","atc_code_human":"L04AA28","atcvet_code_veterinary":"","therapeutic_area_mesh":"Graft Rejection;Kidney Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/09/2020","first_published_date":"23/09/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/nulojix"},{"category":"Human","name_of_medicine":"Prevymis","procedure_number":"II/16/G","active_substances":"Letermovir","dhpc_type":"","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J05","atcvet_code_veterinary":"","therapeutic_area_mesh":"Cytomegalovirus Infections","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"11/09/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/prevymis"},{"category":"Human","name_of_medicine":"Insuman","procedure_number":"","active_substances":"Insulin human","dhpc_type":"Type II variation","regulatory_outcome":"","referral_name":"","atc_code_human":"A10AB01;A10AC01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Diabetes Mellitus","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"20/07/2020","first_published_date":"21/07/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/insuman"},{"category":"Human","name_of_medicine":"Myalepta","procedure_number":"EMEA/H/C/004218","active_substances":"Metreleptin","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"A16AA","atcvet_code_veterinary":"","therapeutic_area_mesh":"Lipodystrophy, Familial Partial","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"18/06/2020","first_published_date":"18/06/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/myalepta"},{"category":"Human","name_of_medicine":"Suboxone","procedure_number":"EMEA/H/C/000697","active_substances":"buprenorphine;naloxone","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"N07BC51","atcvet_code_veterinary":"","therapeutic_area_mesh":"Opioid-Related Disorders","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"18/06/2020","first_published_date":"18/06/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/suboxone"},{"category":"Human","name_of_medicine":"Ondexxya","procedure_number":"","active_substances":"andexanet alfa","dhpc_type":"Safety signal","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"V03AB","atcvet_code_veterinary":"","therapeutic_area_mesh":"Drug-Related Side Effects and Adverse Reactions","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"17/06/2020","first_published_date":"17/06/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ondexxya"},{"category":"Human","name_of_medicine":"Flucytosine","procedure_number":"EMEA/H/A-31/1481","active_substances":"flucytosine","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products","atc_code_human":"J02AX01","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"04/06/2020","first_published_date":"04/06/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/flucytosine"},{"category":"Human","name_of_medicine":"Xeloda / Capecitabine Accord / Capecitabine Medac / Capecitabine Teva / Ecansya (previously Capecitabine Krka) / Teysuno","procedure_number":"EMEA/H/A-31/1488","active_substances":"Fluorouracil;capecitabine;tegafur","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products","atc_code_human":"L01BC06;L01BC53;L01BC02","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"04/06/2020","first_published_date":"04/06/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/xeloda-capecitabine-accord-capecitabine-medac-capecitabine-teva-ecansya-previously-capecitabine-krka-teysuno"},{"category":"Human","name_of_medicine":"Tepadina","procedure_number":"","active_substances":"thiotepa","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L01AC01","atcvet_code_veterinary":"","therapeutic_area_mesh":"Hematopoietic Stem Cell Transplantation","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"01/06/2020","first_published_date":"02/06/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/tepadina"},{"category":"Human","name_of_medicine":"Brivudine","procedure_number":"PSUSA/00000434/201907","active_substances":"brivudine","dhpc_type":"Periodic safety update single assessment","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J05AB15","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"12/05/2020","first_published_date":"12/05/2020","last_updated_date":"12/05/2020","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/brivudine"},{"category":"Human","name_of_medicine":"Polivy","procedure_number":"EMEA/H/C/004870","active_substances":"polatuzumab vedotin","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L01FX06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Lymphoma, B-Cell","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"04/05/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/polivy"},{"category":"Human","name_of_medicine":"Cyproterone","procedure_number":"EMEA/H/A-31/1488","active_substances":"cyproterone","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Cyproterone-containing medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Androgen Antagonists","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"29/04/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/cyproterone"},{"category":"Human","name_of_medicine":"Esmya / Ulipristal Acetate Gedeon Richter","procedure_number":"EMEA/H/A-31/1496","active_substances":"ulipristal acetate","dhpc_type":"Interim measures","regulatory_outcome":"Suspension","referral_name":"Ulipristal acetate 5mg medicinal products","atc_code_human":"","atcvet_code_veterinary":"","therapeutic_area_mesh":"Leiomyoma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"23/03/2020","first_published_date":"23/03/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/esmya-ulipristal-acetate-gedeon-richter"},{"category":"Human","name_of_medicine":"Mepact","procedure_number":"","active_substances":"mifamurtide","dhpc_type":"Quality defect","regulatory_outcome":"","referral_name":"","atc_code_human":"L03AX15","atcvet_code_veterinary":"","therapeutic_area_mesh":"Osteosarcoma","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"25/02/2020","first_published_date":"25/02/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/mepact"},{"category":"Human","name_of_medicine":"Estradiol","procedure_number":"EMEA/H/A-31/1482","active_substances":"estradiol","dhpc_type":"Referral - Article 31","regulatory_outcome":"Variation","referral_name":"Estradiol-containing (0.01% w/w) medicinal products for topical use","atc_code_human":"G03CA03","atcvet_code_veterinary":"","therapeutic_area_mesh":"","species":"","other_related_medicines_nationally_authorised":"Linoladiol N; Linoladiol; Linoladiol Estradiol; Estradiol Wolff; Montadiol","dissemination_date":"20/02/2020","first_published_date":"20/02/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/estradiol"},{"category":"Human","name_of_medicine":"Picato","procedure_number":"EMEA/H/A-20/1489/C/2275/1489","active_substances":"Ingenol mebutate","dhpc_type":"Interim measures;Referral - Article 20 procedure","regulatory_outcome":"Suspension","referral_name":"Picato","atc_code_human":"D06BX02","atcvet_code_veterinary":"","therapeutic_area_mesh":"Keratosis, Actinic","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"27/01/2020","first_published_date":"14/02/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/picato"},{"category":"Human","name_of_medicine":"Ecalta","procedure_number":"","active_substances":"anidulafungin","dhpc_type":"Quality defect","regulatory_outcome":"Variation","referral_name":"","atc_code_human":"J02AX06","atcvet_code_veterinary":"","therapeutic_area_mesh":"Candidiasis","species":"","other_related_medicines_nationally_authorised":"","dissemination_date":"","first_published_date":"14/02/2020","last_updated_date":"","dhpc_url":"https://www.ema.europa.eu/en/medicines/dhpc/ecalta"}]